Portal de Periódicos da CAPES

420 SUPERSTIMULATION OF ANGUS DONORS WITH A SINGLE INTRAMUSCULAR INJECTION OF FOLLTROPIN®-V

2010; CSIRO Publishing; Volume: 22; Issue: 1 Linguagem: Inglês

10.1071/rdv22n1ab420

1448-5990

A. Tríbulo, H. Tríbulo, R. Tríbulo, D. Carballo Guerrero, Paula Tríbulo, Dragan Rogan, R.J. Mapletoft, G. A. Bó,

Reproductive Physiology in Livestock

Two experiments were designed to determine the superovulatory response of Angus donors treated with a single injection of Folltropin®-V diluted in a slow release formulation (SRF; Bioniche Animal Health Inc., Belleville, Ontario, Canada). Experiment 1 was designed to compare superovulatory response in Angus donor cows (n = 29 per group) treated with a single i.m. injection of Folltropin®-V diluted in SRF with cows treated using the traditional twice-daily i.m. injection treatment schedule. On Day 0, all cows received 5 mg of estradiol-17β plus 50 mg of progesterone and a Cue-Mate® (Bioniche Animal Health). On Day 4, cows were superstimulated with 400 mg of NIH-FSH-P1 Folltropin®-V in twice-daily decreasing doses over 4 days or in a single i.m. injection in the neck. The single injection was prepared by diluting the Folltropin®-V lyophilized powder in 1 mL of saline for injection and mixed with 9 mL of the SRF in the syringe immediately before administration. In the am and pm of Day 6, all cows received PGF2 and Cue-Mates® were removed in the pm. In the am of Day 8, cows received 12.5 mg of porcine LH (Lutropin®-V; Bioniche Animal Health) and were inseminated 12 and 24 h later. Ova/embryos were collected nonsurgically on Day 15 and evaluated following IETS recommendations. Means were compared between groups by t-test Mean (±SEM) number of ova/embryos and transferable embryos were 13.7 ± 2.1 and 7.1 ± 1.3 v. 12.3 ± 1.5 and 5.3 ± 0.8 for donors treated with the single v. twice-daily injections, respectively (P > 0.4). Experiment 2 was designed to confirm the results of Experiment 1 and to compare the effect of different dosages of Folltropin®-V on embryo production in Angus cows. Cows (n = 23) were superstimulated by 6 treatment protocols (2 × 3 factorial) in a crossover design (i.e. all cows received the 6 treatments and all treatments were represented on each collection day). Cows received the same treatments as cows in Experiment 1 except that the dosages of Folltropin®-V used were 200, 300, or 400 mg. Statistical analysis (ANOVA) revealed a significant effect of dosage of Folltropin®-V on embryo production, but there was no effect of treatment (i.e. single v. twice-daily injections; P > 0.2), nor was there a treatment by dosage interaction (P > 0.7). Mean (± SEM) number of ova/embryos and transferable embryos were 10.3 ± 0.9 and 5.4 ± 0.6 v. 11.3 ± 0.6 and 5.6 ± 0.5 for donors treated with the single or twice-daily injections, respectively (P > 0.2). Furthermore, the mean number of ova/embryos and transferable embryos were higher in cows treated with 400 mg (13.9 ± 1.1 and 6.5 ± 0.7) and 300 mg (12.0 ± 1.0 and 6.1 ± 0.7) of Folltropin®-V than those treated with 200 mg (6.6 ± 0.7 and 4.0 ± 0.5). In summary, superstimulation of Angus donor cows with a single i.m. injection of Folltropin®-V diluted in an SRF resulted in comparable embryo production to the traditional twice-daily i.m. administration of Folltropin®-V over 4 days. Although response did not differ between 300 and 400 mg, results suggest that 300 mg of Folltropin®-V given i.m. by a single or twice-daily injections is the most appropriate dose for Angus donor cows.